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Abstract
Background: Our aim was to investigate the role of nicotinic acetylcholine receptors (nAChRs) in in-vitro
osteoclastogenesis and in in-vivo bone homeostasis.
Methods: The presence of nAChR subunits as well as the in-vitro effects of nAChR agonists were investigated by ex
vivo osteoclastogenesis assays, real-time polymerase chain reaction, Western blot and flow cytometry in murine
bone marrow-derived macrophages differentiated in the presence of recombinant receptor activator of nuclear
factor kappa B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). The bone phenotype of mice
lacking various nAChR subunits was investigated by peripheral quantitative computed tomography and
histomorphometric analysis. Oscillations in the intracellular calcium concentration were detected by measuring the
Fura-2 fluorescence intensity.
Results: We could demonstrate the presence of several nAChR subunits in bone marrow-derived macrophages
stimulated with RANKL and M-CSF, and showed that they are capable of producing acetylcholine. nAChR ligands
reduced the number of osteoclasts as well as the number of tartrate-resistant acidic phosphatase-positive
mononuclear cells in a dose-dependent manner. In vitro RANKL-mediated osteoclastogenesis was reduced in mice
lacking α7 homomeric nAChR or β2-containing heteromeric nAChRs, while bone histomorphometry revealed
increased bone volume as well as impaired osteoclastogenesis in male mice lacking the α7 nAChR. nAChR ligands
inhibited RANKL-induced calcium oscillation, a well-established phenomenon of osteoclastogenesis. This inhibitory
effect on Ca2+ oscillation subsequently led to the inhibition of RANKL-induced NFATc1 and c-fos expression after
long-term treatment with nicotine.
Conclusions: We have shown that the activity of nAChRs conveys a marked effect on osteoclastogenesis in mice.
Agonists of these receptors inhibited calcium oscillations in osteoclasts and blocked the RANKL-induced activation
of c-fos and NFATc1. RANKL-mediated in-vitro osteoclastogenesis was reduced in α7 knockout mice, which was
paralleled by increased tibial bone volume in male mice in vivo.
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Background
Acetylcholine (ACh) was the first neurotransmitter to be
discovered [1]. It is an essential mediator of both the
central and the peripheral nervous system [2, 3]. ACh
acts on two main types of receptors: nicotinic acetylcho-
line receptors (nAChRs), which are ligand-gated ionotro-
pic receptors, and muscarinic acetylcholine receptors
(mAChRs), which are metabotropic G-protein coupled
receptors [4]. Neuronal nAChRs are pentamers com-
posed of either homomeric or heteromeric combina-
tions of twelve different nicotinic receptor subunits: α2
through α10 and β2 through β4 [5]. In addition to its
role in the nervous system, ACh is increasingly recog-
nized as an important modulator in various non-
neuronal tissues [6–8].
nAChRs have also been identified on cells known to
be essential for the maintenance of bone homeostasis,
such as osteoblasts and osteoclasts [9–12]. In
addition, other components involved in cholinergic
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transmission, including the vesicular ACh trans-
porter, but also the enzyme choline acetyltransferase
needed for the synthesis of Ach, have been reported
to be present in murine osteoblasts [13]. Moreover,
recent studies have revealed the presence of cholin-
ergic innervation in bone marrow, suggesting a po-
tential regulatory role of ACh on all bone marrow
cells including osteoclasts, but possibly also osteo-
blasts [12, 14, 15].
Osteoclasts are formed by the fusion of hematopoetic
mononuclear cells [16]. This process requires the pres-
ence of macrophage colony-stimulating factor (M-SCSF)
and receptor activator of nuclear factor kappa B ligand
(RANKL) [16]. Recently, several studies have implicated
nAChRs and mAChRs in regulating osteoclastogenesis;
however, their effects on osteoclastogenesis have not yet
been fully elucidated [17–20]. nAChR agonists, such as
nicotine or carbamylcholine, have been shown to reduce
the formation of osteoclasts in vitro [12, 17], while other
studies have reported a stimulating effect of nAChR ago-
nists on osteoclastogenesis [18, 21, 22]. Moreover, nico-
tine was also shown to affect osteoblast differentiation
and function [23–25]. Mice lacking the α2 nAChR sub-
unit or the M2 mAChR have increased bone resorption
and low bone mass due to increased osteoclastogenesis
[12, 19], while female α7 knockout mice exhibited
significantly increased bending stiffness and cortical
thickness, as well as reduced gene expression of the
osteoclast marker cathepsin K [20].
The potential relevance of cholinergic regulation in
bone homeostasis under pathological conditions, such as
chronic inflammation, was further highlighted by investi-
gations into α7-deficient mice which exhibit increased
bone loss as compared to wild-type (WT) mice in an
animal model of arthritis [26].
Our aim was to investigate the role of nAChRs in
osteoclasts in detail, and to examine the effect of
these receptors on osteoclastogenesis and bone turn-
over in WT and knockout mice lacking individual
nAChR subunits.
Methods
Mice
Experiments were performed on C57Bl/6 (WT) mice
and mice with deletions of the nAChR subunit genes α7
[27], β2 [28] and β4 [29]. Mice used in this study were
backcrossed onto C57Bl/6 background for 6 (β4), 7 (α7)
or 12 (β2) generations after germ line transmission and
kept at the Center for Brain Research, Medical University
of Vienna, Austria. All data were generated from sex- and
age-matched littermates. The Institutional Animal Care
and Use Committee of the Medical University Vienna
approved all mouse procedures.
Osteoclastogenesis from bone marrow-derived
macrophages
Bone marrow cells obtained from the femurs and tibias
of wild-type and knockout mice were cultured in alpha-
MEM medium (Gibco) containing 10 % fetal calf serum
and 1 % penicillin-streptomycin. For in vitro osteoclast
formation, we used mouse bone marrow cells stimulated
in Petri dishes for 3 days with M-CSF 10 ng/ml (bone
marrow macrophages; BMMs). BMMs were subse-
quently plated on 96-well plates and supplemented with
30 ng/ml M-CSF and 50 ng/ml RANKL with media/
cytokine changes every 2 days. After 5–6 days under
these osteoclastogenic conditions, we performed staining
for tartrate-resistant acidic phosphatase (TRAP) and im-
aged the plates using an inverted microscope. The num-
ber of osteoclasts (OCs), defined as TRAP-positive cells
containing ≥3 nuclei (TRAP-positive multinucleated
cells), was counted manually in each well, while the
number of cells containing <3 nuclei (TRAP-positive or
TRAP-negative mononucleated cells) were counted in
three power fields in each well and expressed as percent
of control from at least three independent cultures. All
agonists and antagonists were administered to BMMs
together with M-CSF and RANKL unless otherwise
noted.
In vivo osteoclastogenesis
Calvarial bone resorption was induced by subcutaneous
injection of lipopolysaccharide (LPS; Sigma) above the
calvaria into 7-week-old C57Bl/6 mice. The heads of
anesthetized mice were shaved to receive subcutaneous
injections above the calvaria in the midline of the skull
located between the ears and eyes. A total of 20 mice
were divided into four groups: group 1 (n = 5), injections
of 500 μg/ml LPS and on alternate days an equivalent
dose of phosphate-buffered saline (PBS); group 2 (n = 5),
injections of 500 μg/ml LPS together with 4 mg/kg nico-
tine (in a single volume of 100 μl) and on alternate days
4 mg/kg nicotine alone (100 μl); group 3 (n = 5), daily
injections of 4 mg/kg nicotine (100 μl); and group 4
(n = 5) daily injections of PBS (100 μl) for a period of
1 week. Animals were sacrificed by cervical dislocation;
calvariae were removed and suspended in phosphate-
buffered formalin for 6 hours. Following 7 days of decalci-
fication in ethylenediaminetetraacetic acid (EDTA), tissues
were embedded in paraffin, and serial sections were
stained for TRAP (Sigma). Osteoclast numbers and
eroded areas were determined as previously described [30]
by Osteomeasure® software.
Immunocytochemical staining
BMMs stimulated with M-CSF and RANKL were
cultured on 12-mm plain glass coverslips and stained
with anti-choline acetyl transferase antibody (AB144P;
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Millipore, 1:25) for 1 hour, followed by a secondary, bio-
tinylated rabbit-antigoat IgG (Vector) for 30 minutes,
avidin/biotin complex (Vector) for 45 minutes and di-
aminobenzidine substrate (Vector) for 10 minutes.
Coverslips were finally stained with Mayer’s hematoxylin
solution and were mounted on glass slides.
Quantitative and semi-quantitative real-time polymerase
chain reaction
For investigating the presence/absence of nAChR sub-
units we performed semi-quantitative real-time polymer-
ase chain reaction (RT-PCR) analysis while quantitative
RT-PCR analysis was undertaken to investigate changes
in RANKL-dependent genes. Nucleus interpeduncularis
was homogenized using an Ultra-Turrax-Disperser.
Messenger RNA was extracted from BMMs stimulated
with M-CSF and RANKL as well as nucleus interpedun-
cularis homogenate using the RNeasy Kit (Qiagen). RNA
quality was ascertained by measuring absorption at 260
and 280 nm and calculating the A260/A280 ratio, which
was 1.8–2.0 for the RNA samples used in our experi-
ments. Care was taken when creating complementary
DNA (cDNA) templates to obtain libraries free of inhibi-
tors. Reaction efficiency for the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase as well as all
genes of interest was ensured by the creation of standard
curves using measurements obtained over a dilution
range. A volume of 800 nl/1 μl cDNA was used for the
semi-quantitative/quantitative PCR, respectively. For the
semiquantitative RT-PCR, cDNA was amplified using
REDTaq-DNA Polymerase (Sigma-Aldrich) and the
primers listed in Additional file 1: Table S1 were ana-
lyzed visually on an acrylamide gel. Quantitative RT-
PCR expression of mRNA was detected and quantified
using SYBR Green PCR Master Mix (Applied Biosys-
tems). The following primers were investigated (genes):
nicotinic receptor subunits: α2-7, 9, 10 as well as β2–4
(see Additional file 1: Table S1 for primer sequences),
cathepsin K (Ctsk), matrix-metalloprotease 9 (Mmp9),
tartrate-resistant acidic phosphatase (Acp5), nuclear fac-
tor of activated T cells c1 (Nfatc1), and receptor activa-
tor of nuclear factor kappa beta (Tnfrsf11a).
Bone morphology
We performed histomorphometry using the Osteomeasure®
software as previously described [30] in 16-week old
male β4–/– and α7–/– mice as well as WT age-
matched littermates. We measured bone mineral
density (BMD) by peripheral quantitative computed
tomography (pQCT) with an XCT Research M+ pQCT
machine (Stratec Medizintechnik). We measured three
slices in the proximal tibia and calculated BMD values
as the mean of three slices, using a voxel size of
0.07 mm and a threshold of 400 mg/cm3.
Flow cytometry and MTT assay
For flow cytometric analyses, we used a BD FACS Canto
II (BD). We stained for CD11b (AM1/70), GR1 and F4/
80 (all from BD Biosciences). We characterized osteo-
clast precursors as (CD11bhigh)/(GR1low) cells. For apop-
tosis evaluation, M-CSF- and RANKL-stimulated BMMs
were stained for Annexin V (Axxora LLC) and 7-
Aminoactinomycin-D (7-AAD) (Fluka Sigma-Aldrich)
[31]. We characterized live cells as Annexin V low/7-
AAD low, apoptotic cells as Annexin V high/7-AAD
low, and dead cells as Annexin V high/7-AAD high, re-
spectively. To distinguish from small cellular debris, for-
ward and right angle scatter gates have been defined by
contour plot and the probability scaling method, where
regions were drawn to contain 95 % of the relevant
lymphoid and myeloid cell populations. Gates were lim-
ited in their forward angle scatter dimension not to con-
tain events falling in channel numbers higher than
250,000, thereby eliminating the majority of cellular
clusters or multiplets. Acquisition was stopped when
10,000 events within a separate lymphoid region had
been reached. The number of myeloid cells acquired was
in proportional relations between equivalent cultures, al-
beit slightly varying by culture conditions. Percentages
were read out as precentage of parent, where the parent
region comprised of lymphoid and myeloid cell popula-
tions not containing small cellular debris or large cellu-
lar clusters. Thresholds for staining positivity were
determined using unstained cell preparations by just
omitting the addition of fluorescein-isothiocyanate
(FITC)-conjugated Annexin-V or 7-AAD as a viability
dye. For each antibody, appropriate isotype-matched
control staining was performed to distinguish positive
staining from non-specific noise. We used the following
fluorophores: Annexin V: FITC; CD11b and F4/80:
Allophycocyanine; and GR-1: R-phycoerythrine. Cytotoxicity
was evaluated using a standard MTT assay (Merck
Millipore) by measuring absorbance on an enzyme-linked
immunosorbent assay (ELISA) plate reader.
Calcium measurement
Mouse bone marrow cells were first cultured for 2 days
in the presence of recombinant mouse M-CSF
(10 ng/ml) (BMMs). Non-adherent cells were then plated
at 2 × 105 cells/cm2 density and cultured in the presence
of 50 ng/ml recombinant mouse M-CSF and 50 ng/ml
mouse RANKL for 72 hours. For Ca2+ measurements, the
cells were incubated with 5 μM Fura-2-AM (Tocris
Bioscience) and 0.05 % pluronic F127 (Sigma-Aldrich).
Fluorescence intensity was measured using excitation
wavelengths of 340 and 380 nm, and the emitted fluores-
cence at 510 nm (fluorescence ratio 340/380 nm).
Changes in the fluorescence ratio 340/380 nm are shown
as a function of time. Evaluation of the images was
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performed with MetaFluor® software (Molecular Devices).
The images were scanned and plotted with an interval of
5 seconds. Graphs are representative of four independent
cells from three independent experiments.
Western blotting
BMMs stimulated with 30 ng/ml M-CSF and 50 ng/ml
RANKL were lysed in radioimmunoprecipitation buffer
(RIPA-buffer; 10 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1 % NP-40, 1 % sodium deoxycholate, 0.1 % SDS, 1 mM
EDTA) supplemented with protease inhibitors (Roche).
Lysates were cleared by centrifugation in a microcentri-
fuge. Protein content was determined using the Bradford
protein assay (Bio-Rad). To reduce and denature the
protein, samples were boiled in Laemmli sample buffer.
Lysates were resolved by SDS-PAGE. This was followed
by electrotransfer onto nitrocellulose membrane, with a
loading amount of 30 μg protein. After blocking with
5 % milk, membranes were incubated with primary
antibodies NFATC1 (Santa-Cruz), c-FOS (Cell Signalling)
and Actin (Cytoskeleton) according to the manufac-
turer’s protocol and then exposed to horseradish
peroxidase-conjugated secondary antibodies (Jackson).
Specific bands were detected with the ECL-detection
kit (Pierce) on Amersham Hyperfilm ECL (GE
Healthcare). Protein expression was quantified using
Image J® software.
Statistical analyses
All experiments were performed at least three times (or
on at least three individual mice) with comparable re-
sults. Data are presented as bar graphs showing the
mean ± standard deviation (SD). Statistical analysis was
performed using one-way analysis of variance with
Dunnett's post-hoc test for comparisons involving more
than three groups and Student’s two-population un-
paired t-test for comparisons involving two groups, both
performed using GraphPad Prism® version 4.00 for
Windows (GraphPad Software, San Diego California,
USA). Asterisks in figures indicate the following p-values:
*p < 0.05; **p < 0.005; ***p < 0.001.
Results
Osteoclast formation is inhibited by nAChR ligands
in vitro
We first isolated cells from the bone marrow of mice
and stimulated them with M-CSF to generate BMMs.
We then showed that following stimulation with M-CSF
and RANKL these cells stain positively for choline-
acetyltransferase, the enzyme responsible for acetylcho-
line production (Fig. 1a). Moreover, in line with previous
findings [12, 17], we could demonstrate that BMMs ini-
tially stimulated with M-CSF and subsequently with both
M-CSF and RANKL express mRNA of several alpha
nAChR subunits, including α subunits, 2–7, 9 and 10 as
Fig. 1 Osteoclast formation is inhibited by nAChR ligands in vitro. a (Left panel) Immunocytochemical staining of choline acetyl transferase (ChAT)
(Millipore, dilution 1:50) in BMMs stimulated with M-CSF and RANKL and (right panel) control staining with secondary antibody (AB) (biotinylated
rabbit-antigoat IgG) only. Scale bars = 100 μm. b–g Effect of nAChR ligands on osteoclastogenesis. Images in the bottom panel are representative
of corresponding experiments; scale bar = 100 μm; b nicotine; c epibatidine; d PNU282987; e nicotine after pretreatment with 100 μM mecamylamine;
f mecamylamine; g alpha-bungarotoxin. BTX alphabungarotoxin; TRAP tartrate-resistant acidic phosphatase
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well the beta subunits 2–3 (Additional file 2: Figure S1),
implying a potential role of not only homomeric but also
heteromeric nAChRs on osteoclastogenesis.
In order to evaluate nAChRs, we utilized both non-
specific agonists (nicotine, epibatidine) as well as a specific
agonist (PNU282987) in the in vitro osteoclastogenesis
assay. Interestingly, both the non-specific agonist nicotine
but also the α7-specific agonist PNU282987 caused an in-
crease in OC numbers at low doses, which was significant
in the case of PNU282987.
However, at higher concentrations all agonists, includ-
ing epibatidine, caused a marked, dose-dependent inhib-
ition of OC formation (Fig. 1b-d).
We next examined whether the inhibition of OCs caused
by the agonists is nAChR-mediated. Therefore, we added
the non-selective, non-competitive nAChR antagonist meca-
mylamine to the culture. However, at lower concentrations
mecamylamine was unable to prevent the inhibitory effect
of nicotine (Fig. 1e). Moreover, when mecamylamine was
administered at high doses, we observed a similar inhibition
of OCs as seen with the agonists (Fig. 1f). Interestingly, not
only the non-selective antagonist mecamylamine, but also
the α7 nAChR selective antagonist alpha-bungarotoxin
caused a similar, inhibition of OC formation (Fig. 1g). Taken
together we could demonstrate that ligands of nAChRs, in-
cluding both agonists and antagonists, inhibit OCs in vitro.
Nicotine reversibly blocks RANKL-induced osteoclast
formation in vitro
In order to further elucidate this blocking effect, we
added the nAChR agonist nicotine either to the first,
M-CSF-driven, and/or to the second, predominantly
RANKL-driven, phases of osteoclastogenesis. When we
administered nicotine parallel only to the first, but not the
second, phase we observed no inhibition of OC formation
(Fig. 2a). However, when the agonist at a high-dose was
Fig. 2 Nicotine reversibly blocks RANKL-induced osteoclast formation in vitro. a Effect on nicotine on the first (M-CSF-driven) phase of osteoclastogenesis. b
Effect on nicotine on the second (M-CSF and RANKL-driven) phase of osteoclastogenesis. c–g Effect of nicotine on expression of RANKL-induced genes: c
TRAP; d cathepsin K; e MMP9; f NFATc1; g RANK. h Effect of nicotine on osteoclastogenesis in the presence and absence of M-CSF in the second phase. i
Osteoclast formation after 7 days of treatment with 50 ng/ml RANKL and 30 ng/ml M-CSF in the presence/absence of nicotine 500 μg/ml; osteoclast formation
after 12 days of treatment with 50 ng/ml RANKL and 30 ng/ml M-CSF with presence/absence of nicotine 500 μg/ml in the first 7 days of the assay. M-CSF
Macrophage colony-stimulating factor, MMP9 matrix-metalloprotease 9, NFATc1 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1, Nic
nicotine, RANK receptor activator of nuclear factor kappa B, RANKL receptor activator of nuclear factor kappa B ligand, TRAP tartrate-resistant acidic phosphatase
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added concomitant to the second, M-CSF and RANKL-
driven, phase we detected a marked reduction in OC num-
bers (Fig. 2b). Moreover, this effect was accompanied by re-
ductions in the relative expression of RANKL-dependent
genes including TRAP, cathepsin K, and matrix metallo-
proteinase 9 (Fig. 2c–e); we found, however, no significant
change in the expression of receptor activator of nuclear
factor kappa B (RANK) and NFATc1 (Fig. 2f and g).
To elaborate the blocking effect of nicotine on the sec-
ond phase in more detail we performed experiments in
which we administered RANKL without M-CSF, where-
upon we observed a decrease in OC numbers which was
further reduced upon administration of high-dose nico-
tine together with RANKL (Fig. 2h).
In order to assess the reversibility of the effect of high-
dose nicotine on osteoclastogenesis we performed experi-
ments where at the end of our standard in vitro osteoclas-
togenesis assay (day 7) we cultured the cells further with
M-CSF and RANKL for 5 additional days. We could ob-
serve that when nicotine was removed from the medium
after the end of the standard assay on days 7 and cells were
cultured further with M-CSF and RANKL osteoclastogene-
sis was recovered (Fig. 2i). Hence, effects of nicotinic ago-
nists on OC formation appear to be reversible.
Nicotine inhibits in vivo osteoclastogenesis
We next evaluated the effect of the nAChR ligand nicotine
on in vivo osteoclastogenesis. We induced osteoclastogene-
sis by injecting LPS subcutaneously above the calvariae of
WT mice. In mice treated with LPS we observed bone de-
struction accompanied by osteoclastogenesis, which was
significantly reduced when nicotine was administered con-
comitantly to LPS via subcutaneous injection (Fig. 3).
nAChR ligands block differentiation of TRAP-positive
mononuclear cells in vitro
Having shown that nAChR ligands block OC formation
in vitro by interfering with RANKL, we next addressed
the question whether nAChR ligands also affected the
differentiation of TRAP-positive mononuclear cells,
which may fuse to become osteoclasts. Indeed we found
that both non-selective (nicotine, epibatidine) and
selective nAChR agonists (PNU282987) caused a dose-
dependent, significant decrease in the number of TRAP-
positive mononuclear cells (Fig. 4a–c), which we could
also observe upon treatment with the non-selective
nAChR antagonist mecamylamine and selective nAChR
antagonist alpha-bungarotoxin (Fig. 4d and e).
Treatment with nicotine even at the highest concen-
tration (500 μg/ml) did not affect cell-surface expression
of the classical monocyte and granulocyte markers F4/
80, CD11b and GR1 as assessed by flow cytometry
(Fig. 4g–i). We assessed cytotoxicity with the MTT assay
where we observed no difference between control condi-
tions and nicotine treatment (Fig. 4f ). Based on 7AAD-
Annexin V staining, we saw no significant difference in
the percentage of live, apoptotic and dead cells between
control conditions and nicotine treatment (Fig. 4g).
Osteoclastogenesis is reduced in knockout mice lacking
selected nAChR subunits
Having demonstrated marked effects of nAChR ligands
on osteoclastogenesis in vitro, we next evaluated which
nAChR receptor subunits might be involved in this in-
hibition. Taking into account that all heteromeric
nAChRs include a beta subunit, we evaluated mice lack-
ing the beta2 subunit (β2–/–) because this subunit was
Fig. 3 Nicotine inhibits in vivo osteoclastogenesis. Calvarial bone resorption induced by subcutaneous injection of lipopolysaccharide (LPS) above
the calvaria; LPS, phosphate-buffered saline (PBS), nicotine, or nicotine and LPS. Images in the bottom panel are representative of the indicated
groups; scale bars = 100 μm. a Area of erosion/total tissue area; b number of osteoclasts
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expressed in BMMs stimulated with RANKL and M-
CSF and because it is a subunit essential for one of the
major nAChRs, the central nervous system-type (α4β2)
nAChR. We also evaluated animals lacking the beta4
subunit (β4–/–), which was not expressed, but which is
an essential component of the ganglion-type (α3β4)
nAChR.
While we found no differences in the number of OCs
or TRAP-positive mononuclear cells in osteoclastogene-
sis cultures from β4–/– mice as compared to those gen-
erated from WT littermates, the numbers of both types
of cells were significantly reduced in cultures generated
from β2–/– mice (Fig. 5a and b). However, this inhibi-
tory effect observed on osteoclastogenesis in vitro had
no correlate in vivo, since bone volume or trabecular
density in β2–/– animals were not different from WT
littermates (Fig. 5c and d).
Among homomeric nAChRs, the α7 subunit has par-
ticular significance in non-neuronal cells; we therefore
evaluated osteoclastogenesis in mice lacking this subunit
(α7–/– mice). In vitro we found decreased numbers of
OCs and TRAP-positive mononuclear cells in osteoclas-
togenesis cultures generated from α7–/– mice compared
to those generated from WT littermates (Fig. 5a and b).
We next analyzed the tibial bones of male and female
α7–/– animals. We found no significant difference in
BMD or in histomorphometrical analysis in female α7–/–
animals. However we found increased trabecular density
(+26 %) as assessed by microcomputed tomography,
accompanied by increased bone volume/tissue volume
(+23 %) and reduced trabecular separation by histo-
morphometric analysis (Fig. 5e–h) in male α7–/–
animals. This finding was further supported by a re-
duced number of osteoclasts/bone perimeter and re-
duced osteoclast surface/bone surface, in line with a
high bone mass phenotype in vivo (Fig. 5i and j). We
found no difference between the number of osteo-
blasts/bone perimeter and osteoblast surface/bone
surface between any α7–/–, β2–/– mice and WT lit-
termates (Additional file 3: Figure S2).
Fig. 4 Nicotinic AChR ligands block the differentiation of TRAP-positive mononuclear cells in vitro. a Nicotine; b epibatidine; c PNU282987;
d mecamylamine; e alpha-bungarotoxin; f effect of nicotine on cytoxicity as assessed by MTT assay; g percentage of live (Annexin V low/
7-AAD low), apoptotic (Annexin V high/7-AAD low) and dead (Annexin V high/7-AAD high) cells with flow cytometry plots showing representative
experiments (right panels). h–j Effect of nicotine on percentage of cells at the end of the in vitro osteoclastogenesis assay staining positive for marker:
g F4/80; h CD11b; i GR1 low/CD11b+. 7-AAD 7-Aminoactinomycin-D, OD optical density, TRAP tartrate-resistant acidic phosphatase
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To evaluate whether the ligands might be acting on
nAChRs in general rather than on specific subunits, we
treated osteoclastogenesis cultures generated from the
knockout mice with nicotine and observed similar inhib-
ition of osteoclastogenesis as seen in cultures generated
from WT littermates (Fig. 5a and b). Osteoclastogenesis
cultures from α7–/–/β2–/– double knockout animals
did not differ from cultures prepared from α7–/– mice
(data not shown).
nAChR ligands inhibit RANKL-induced Ca2+ oscillation and
activation of NFATc1
Nicotinic AChRs are ion channel receptors which permit
the movement of cations, including Ca2+ [5]. Oscillations
of the intracellular Ca2+ level in turn seem to play an es-
sential role in mediating the effect of RANKL, as osteo-
clastogenesis is impaired in virtually all cases when Ca2+
oscillation is not induced [32–34]. We therefore evalu-
ated the potential effects of nAChR ligands on RANKL-
induced Ca2+ oscillation.
First we found that BMMs cultured in the presence of
M-CSF and RANKL for 3 days showed characteristic
Ca2+ oscillation after 72 hours of treatment with
RANKL, while the cells cultured in the presence of
M-CSF alone showed no alterations in intracellular cal-
cium levels (Fig. 6a and b). When we induced Ca2+ oscilla-
tion by pre-treating BMMs with RANKL and thereafter
administered the agonists nicotine and PNU-282987, we
observed an immediate inhibition of RANKL-induced
Ca2+ oscillation (Fig. 6c and d). Of note, we saw the
same effect when we administered the physiological
ligand of nAChR, acetylcholine (ACh) (Fig. 6e). To
evaluate the nature of this inhibition, we added the
antagonist alpha-bungarotoxin, which caused a similar
effect (Fig. 6f ). We next added mecamylamine shortly
before treating oscillating BMMs with ACh and found
that ACh failed to inhibit Ca2+ oscillation under these
conditions (Fig. 6g). BMMs subjected to prolonged
exposure (3 days) with high-dose nicotine (100 μg/ml)
and RANKL, administered together, failed to induce
the characteristic Ca2+ oscillations (Fig. 6h).
We next asked whether this blockade also affected
downstream elements of the RANK signaling pathway,
such as the transcription factors NFATc1 and c-fos
Fig. 5 Osteoclastogenesis is partly inhibited in nAChR subunit –/– mice. a, b Osteoclastogenesis in WT, α7–/–, β2–/– and β4–/– mice with or without
500 μg/ml nicotine treatment. Images in the right panel are representative of the corresponding experiments; scale bars = 100 μm. c, e Bone volume/
tissue volume; d, f trabecular density; g trabecular thickness; h trabecular separation; i number of osteoclasts/bone perimeter; j osteoclast surface/bone
surface. TRAP tartrate-resistant acidic phosphatase, WT wild-type
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[35, 36]. Therefore, we isolated protein from osteoclasto-
genesis cultures at various time points throughout the
assay and performed Western blot experiments. Indeed,
nicotine inhibited the induction of c-fos after 24-hour
stimulation with RANKL, and of NFATc1 after 24-hour,
48-hour or 7 days of stimulation with RANKL (Additional
file 4: Figure S3).
Discussion
The RANK receptor and its ligand, RANKL, play key
roles in osteoclastogenesis both within the framework of
physiological bone turnover and in various diseases char-
acterized by inflammatory bone loss [16]. The central
role of RANKL in osteoclast formation and bone deg-
radation is further underlined by successful therapeutic
approaches targeting this pathway. Denosumab, a
RANKL-specific monoclonal antibody, is not only an ef-
fective treatment for postmenopausal osteoporosis, but
also reduces local bone loss in patients with rheumatoid
arthritis [37, 38]. The finding that nAChR activation can
interfere with RANK signaling is supported by the fol-
lowing findings: 1) when nicotine was added only to the
first (solely M-CSF-driven) phase of osteoclast differenti-
ation, it had no effect on OC generation; 2) when nico-
tine was present during the second phase in parallel
with MCSF and RANKL, it caused an inhibitory effect;
3) even when M-CSF was absent from the second phase,
nicotine was able to reduce osteoclastogenesis; and 4)
the relative expression of RANKL-dependent gene, in-
cluding TRAP, cathepsin K, matrix metalloproteinase 9
and NFATc1, was decreased in OCs treated with
nicotine.
Herein we demonstrate that nAChRs are crucially in-
volved in RANKL-induced osteoclastogenesis by inhibit-
ing Ca2+ oscillations, which in turn blocks RANKL-
induced activation of c-fos and NFATc1. In contrast to
our findings, it has been recently suggested that nAChR
agonists have no effect on osteoclastogenesis in vitro
[12]; however, the ligands were used at lower concentra-
tions than we utilized in our study. Tanaka et al. admin-
istered nicotine at doses comparable to those used here,
and observed a reduction in the number of large OCs
and the resorptive index, but an increase in the number
of small OCs suggesting a reduction in fusion [17]. We
were also able to observe an increase in the number of
osteoclasts upon administration of low-dose nicotine
and PNU282987. Thus nicotinic agonists at low concen-
tration may favor the generation of osteoclasts, whereas
high concentrations inhibit osteoclastogenesis. Interest-
ingly it has been suggested that different nAChRs may
also convey opposing effects as evidenced by recent
studies, which described increased in vitro osteoclasto-
genesis as well as a significant, though modest, decrease
in the systemic bone mass of α2–/– mice [12] and in-
creased bending stiffness and cortical thickness in female
α7–/– mice, while male counterparts showed no
Fig. 6 Nicotinic AChR ligands inhibit RANKL-induced Ca2+ oscillation. a, b Intracellular Ca2+ level in BMMs, a cultured in the presence of M-CSF for
72 hours and b cultured in the presence of M-CSF and RANKL for 72 hours. c–g Effect of acute administration of nAChR ligands on intracellular Ca2+
level in BMMs cultured in the presence of M-CSF and RANKL for 72 hours. c Nicotine (Nic; 100 μg/ml); d PNU282987 (PNU; 5–10 μM); e acetylcholine
(Ach; 10 μM); f alpha-bungarotoxin (BTX: 100 nM); g mecamylamine (Mec; 10 μM) and ACh (10 μM). h Intracellular Ca2+ levels in BMMs cultured in the
presence of M-CSF, RANKL and nicotine (100 μg/mL) for 72 hours
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difference as compared to WT [20]. However, male α7
β2–/– exhibited a significant increase in BMD when
compared to WT mice [39]. Interestingly, we found an,
albeit modest, increased bone mass in male α7–/– mice,
which we could not demonstrate in female α7–/– mice.
Gender disparity with regard to bone phenotype is not
uncommon and has been described among others in
CB1–/– or GPR55–/– mice [40, 41]. In both of these
cases males exhibited an osteopetrotic phenotype which
females did not, and which was not otherwise explain-
able. In line with previous studies, which showed no
change in gene expression of osteoblast markers, we
found no change in the osteoblast phenotype in α7–/–
mice [19, 20]. Taken together it appears that high levels
of nAChR stimulation may have an overall negative ef-
fect on osteoclastogenesis but actions mediated via the
α7 receptor may indeed be different and positive in
nature.
Our observation that nAChR antagonists also inhibit
osteoclastogenesis, coupled with our results showing re-
duced osteoclastogenesis in α7–/– mice, can be inter-
preted in the context of desensitization, a key property
of nAChRs. Depending on the receptor subtype and the
type of agonist, as well as the duration of exposure to
nAChRs, agonists have been shown to alter the affinity
state of the receptor inducing desensitization, leading to
a functional blockade of the receptor [42, 43]. In particu-
lar, nicotine and certain experimental α7-selective partial
agonists are known to produce a transient activation of
α7 receptors followed by a period of prolonged residual
inhibition or desensitization [44]. While we derived the
dosage of nicotine from published studies [17, 18], due
to the fact that we used high doses we cannot exclude
the possibility that the inhibition seen with the high-
dose nAChR ligands is due to either effects on mAChRs,
non-receptor mediated effects (such as the blocking of
additional ion channels), or to other factors involved in
the regulation of osteoclastogenesis.
Oscillating levels of intracellular calcium appear to
be critical for osteoclastogenesis primarily by inducing
the dephosphorylation and shuttling of NFATc1 into
the nucleus, where it plays a decisive role in the regula-
tion of osteoclastogenesis [32–34]. After observing the
marked acute effect of both nAChR agonists and
antagonists on Ca2+ oscillation, we could show that,
indeed, the nAChR agonist nicotine inhibited RANKL-
induced expression and production of NFATc1 and
also had a similar effect on c-fos, an early inducer of
NFATc1 [45].
The fact that cholinergic signaling has an effect on os-
teoclastogenesis is also supported by studies which have
demonstrated that ACh is produced by cells of the im-
munoinflammatory sytem, including lymphocytes [46],
and the fact that bone marrow also possesses its own
sensory and autonomic innervation including cholinergic
neurons [12, 14, 15]. This suggests that, under certain
circumstances, in addition to ACh released from BMMs,
differentiating OCs may also be exposed to ACh released
from neurons, which could then have various effects on
their nAChRs.
Conclusions
Our results suggest that cholinergic agonists inhibit
RANKL-induced osteclastogenesis by interfering with
intracellular calcium levels and consequently with the
NFATc1 signaling pathway. Of note, this complete block-
ade of osteoclastogenesis in vitro was neither due to
toxic effects nor associated with apoptosis, and was
shown to be reversible. However, while high levels of
nAChR activity appear to inhibit RANKL-induced osteo-
clastogenesis, actions mediated by certain nAChRs, in
particular the α7 homomeric receptor, may favor it. Fur-
ther studies are needed to determine the gender-specific
effect of α7 and other nAChRs and mAChRs on bone
homeostasis.
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with quantitative real time PCR. (JPEG 27 kb)
Additional file 2: Figure S1. Semi-quantitative real-time PCR analysis
of nicotinic acetylcholine receptor subunits in murine osteoclasts and
nucleus interpeduncularis. Murine bone marrow-derived osteoclasts
(O); nucleus interpeduncularis (I); – represents negative control; * represent
lanes with molecular weight ladder; nicotinic acetylcholine receptor
subunits are designated by respective Greek letters and Arabic
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Additional file 3: Figure S2. Osteoblast phenotype in nAChR knockout
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Additional file 4: Figure S3. Nicotine inhibits induction of NFATc1 and
c-fos. A, B: Western blot bands and quantification. Protein extracts obtained
from mouse bone marrow-derived macrophages cultured in the presence
of 30 ng/ml M-CSF (C), 30 ng/ml M-CSF and 50 ng/ml RANKL (R), 30 ng/ml
M-CSF and 500 μg/ml nicotine (N), 30 ng/ml M-CSF and 50 ng/ml RANKL
and 500 μg/ml nicotine (R + N) for the indicated timepoints;
A: NFATc1 and actin; B: c-fos and actin. NFATc1:actin and c-fos:actin
ratios are shown in bar graphs in the bottom panel. (JPEG 88 kb)
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